Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study, Clin Orthop Relat Res, issue.270, pp.8-14, 1991. ,
Chemotherapy,en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma, Cancer, vol.32, issue.1, pp.1-11, 1976. ,
DOI : 10.1002/1097-0142(197601)37:1<1::AID-CNCR2820370102>3.0.CO;2-3
Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group., Journal of Clinical Oncology, vol.15, issue.1, pp.76-84, 1997. ,
DOI : 10.1200/JCO.1997.15.1.76
Bisphosphonates: new therapeutic agents for the treatment of bone tumors, Trends in Molecular Medicine, vol.10, issue.7, pp.337-380, 2004. ,
DOI : 10.1016/j.molmed.2004.05.007
Cellular and molecular mechanisms of action of bisphosphonates, Cancer, vol.20, issue.52, pp.2961-78, 2000. ,
DOI : 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L
New Insights Into the Molecular Mechanisms of Action of Bisphosphonates, Current Pharmaceutical Design, vol.9, issue.32, pp.2643-58, 2003. ,
DOI : 10.2174/1381612033453640
Bisphosphonates: Mode of Action and Pharmacology, PEDIATRICS, vol.119, issue.Supplement, pp.150-62, 2007. ,
DOI : 10.1542/peds.2006-2023H
Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI-298, Journal of Bone and Mineral Research, vol.108, issue.8, pp.1467-76, 2000. ,
DOI : 10.1359/jbmr.2000.15.8.1467
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line, British Journal of Cancer, vol.84, issue.7, pp.951-959, 2001. ,
DOI : 10.1054/bjoc.2000.1679
The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro, Anti-Cancer Drugs, vol.12, issue.5, pp.459-65, 2001. ,
DOI : 10.1097/00001813-200106000-00007
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, issue.1, pp.74-86, 2005. ,
DOI : 10.1016/j.bone.2005.02.020
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice, Cancer, vol.91, issue.11, pp.2522-2531, 2005. ,
DOI : 10.1002/cncr.21530
Zoledronic Acid Activates the DNA S-Phase Checkpoint and Induces Osteosarcoma Cell Death Characterized by Apoptosis-Inducing Factor and Endonuclease-G Translocation Independently of p53 and Retinoblastoma Status, Molecular Pharmacology, vol.71, issue.1, pp.333-376, 2007. ,
DOI : 10.1124/mol.106.028837
Mechanisms of Cancer Drug Resistance, Annual Review of Medicine, vol.53, issue.1, pp.615-642, 2002. ,
DOI : 10.1146/annurev.med.53.082901.103929
Exploiting Multidrug Resistance to Treat Cancer, Cold Spring Harbor Symposia on Quantitative Biology, vol.59, issue.0, pp.677-83, 1994. ,
DOI : 10.1101/SQB.1994.059.01.078
Mechanisms and strategies to overcome multiple drug resistance in cancer, FEBS Letters, vol.52, issue.12, pp.2903-2912, 2006. ,
DOI : 10.1016/j.febslet.2006.02.020
An experimental model of osteosarcomas in rats ], Sem Hop, vol.58, pp.28-29, 1982. ,
Studies of bone and soft-tissue tumours induced in rats with radioactive cerium chloride, International Journal of Cancer, vol.3, issue.1, pp.112-121, 1977. ,
DOI : 10.1002/ijc.2910200118
Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies, Cancer Res, vol.30, issue.4, pp.1174-84, 1970. ,
Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu Rev Biochem, vol.62, pp.385-427, 1993. ,
Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil, Cancer Res, vol.41, issue.5, pp.1967-72, 1981. ,
The potential of farnesyltransferase inhibitors as cancer chemotherapeutics, Annu Rev Pharmacol Toxicol, vol.37, pp.143-66, 1997. ,
Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity, Bone, vol.29, issue.4, pp.336-379, 2001. ,
DOI : 10.1016/S8756-3282(01)00589-0
Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation, Mol Pharmacol, vol.59, issue.2, pp.193-202, 2001. ,
Introduction to resistance to anticancer agents, Oncogene, vol.22, issue.47, pp.7262-7266, 2003. ,
DOI : 10.1038/sj.onc.1206932
Recent advances in understanding the mechanism of action of bisphosphonates, Current Opinion in Pharmacology, vol.6, issue.3, pp.307-319, 2006. ,
DOI : 10.1016/j.coph.2006.03.005
Higher Farnesyl Diphosphate Synthase Activity in Human Colorectal Cancer Inhibition of Cellular Apoptosis, Oncology, vol.67, issue.5-6, pp.5-6, 2004. ,
DOI : 10.1159/000082918
Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates, Eukaryot Cell. Bone, vol.5, issue.335, pp.805-816, 2003. ,
How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics, British Journal of Haematology, vol.13, issue.2, pp.202-212, 2003. ,
DOI : 10.1046/j.1365-2141.2002.03257.x
Reduced folate carrier protein expression in osteosarcoma, Cancer, vol.13, issue.9, pp.1958-66, 2003. ,
DOI : 10.1002/cncr.11741
HER-2/ neu Expression in Osteosarcoma Increases Risk of Lung Metastasis and Can Be Associated With Gene Amplification, Journal of Pediatric Hematology/Oncology, vol.25, issue.1, pp.27-32, 2003. ,
DOI : 10.1097/00043426-200301000-00007
The discovery and development of HMG-CoA reductase inhibitors, Atherosclerosis Supplements, vol.5, issue.3, pp.1569-82, 1992. ,
DOI : 10.1016/j.atherosclerosissup.2004.08.026
Statins in the 21st century: end of the simple story?, Expert Opinion on Investigational Drugs, vol.84, issue.69, pp.1755-66, 2001. ,
DOI : 10.1016/S0002-9149(99)00132-0
Chemotherapy resistance in osteosarcoma: current challenges and future directions, Expert Rev Anticancer Ther, vol.6, issue.7, pp.1075-85, 2006. ,
Common musculoskeletal tumors of childhood and adolescence, N Engl J Med, vol.341, issue.5, pp.342-52, 1999. ,
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors, Cancer Genetics and Cytogenetics, vol.145, issue.1, pp.1-30, 2003. ,
DOI : 10.1016/S0165-4608(03)00105-5
Alteration of pRb/p16/cdk4 regulation in human osteosarcoma, International Journal of Cancer, vol.7, issue.5, pp.489-93, 1999. ,
DOI : 10.1002/(SICI)1097-0215(19991022)84:5<489::AID-IJC7>3.0.CO;2-D
Essential role of RSK2 in c-Fos???dependent osteosarcoma development, Journal of Clinical Investigation, vol.115, issue.3, pp.664-72, 2005. ,
DOI : 10.1172/JCI22877DS1
CDK4 gene amplification in osteosarcoma: Reciprocal relationship withINK4A gene alterations and mapping of 12q13 amplicons, International Journal of Cancer, vol.54, issue.2, pp.199-204, 1999. ,
DOI : 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4
The Role of Methotrexate in Osteosarcoma, JNCI Journal of the National Cancer Institute, vol.80, issue.9, pp.626-55, 1988. ,
DOI : 10.1093/jnci/80.9.626
Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncogene, vol.22, issue.47, pp.7265-79, 2003. ,
DOI : 10.1038/sj.onc.1206933
Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells, Biochemical Pharmacology, vol.68, issue.2, pp.283-91, 2004. ,
DOI : 10.1016/j.bcp.2004.03.022
May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol, International Journal of Oncology, vol.29, issue.6, pp.1459-68, 2006. ,
DOI : 10.3892/ijo.29.6.1459